Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors

CLINICALTRIALS.GOV IDENTIFIER: NCT04750954 

DRUG/TREATMENT: lutetium Lu-177 dotatate in combination with M3814 (peposertib)

PHASE: 1b

STATUS: Recruiting 

SPONSOR: National Cancer Institute (NCI)

Dr. Aman Chauhan discusses Lu-177 Dotatate + M3814

DESCRIPTION:

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of peposertib when given together with lutetium Lu-177 dotatate in treating patients with neuroendocrine tumors.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT/Principal Investigator:

Aman Chauhan, MD

EMAIL: axc3268@med.miami.edu